SEC Form 4 · accession 0001179110-18-012004
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Hickey
Officer — SVP, Chief Commercial Officer
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $18.55 | Oct 1, 2018 | A | 149,516 | A | Oct 1, 2019 | Oct 1, 2028 | Common Stock | 149,516 | 149,516 | D |
| Restricted Stock UnitsF2 | $0.00 | Oct 1, 2018 | A | 80,863 | A | Oct 1, 2019 | Oct 1, 2028 | Common Stock | 80,863 | 80,863 | D |
Explanation of responses
- F1This option vests one-fourth on such date and 1/48 monthly thereafter.
- F2This award vests one-fourth on such date and one-fourth on each anniversary thereafter.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney